化疗药物治疗双原发肿瘤继发急性白血病1例及文献复习

杨喜晶; 周福平; 张迁; 钱其军

doi:10.3969/j.issn.1006-0111.2015.05.020

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

化疗药物治疗双原发肿瘤继发急性白血病1例及文献复习

杨喜晶, 周福平, 张迁, 钱其军

文章导航 > 药学实践与服务 > 2015 > 33(5): 453-456

杨喜晶, 周福平, 张迁, 钱其军. 化疗药物治疗双原发肿瘤继发急性白血病1例及文献复习[J]. 药学实践与服务, 2015, 33(5): 453-456. doi: 10.3969/j.issn.1006-0111.2015.05.020

引用本文:

YANG Xijing, ZHOU Fuping, ZHANG Qian, QIAN Qijun. One case of double primary tumors with secondary acute leukemia induced by chemotherapy drugs and literature review[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 453-456. doi: 10.3969/j.issn.1006-0111.2015.05.020

Citation:

YANG Xijing, ZHOU Fuping, ZHANG Qian, QIAN Qijun. One case of double primary tumors with secondary acute leukemia induced by chemotherapy drugs and literature review[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 453-456. doi: 10.3969/j.issn.1006-0111.2015.05.020

化疗药物治疗双原发肿瘤继发急性白血病1例及文献复习

doi: 10.3969/j.issn.1006-0111.2015.05.020

东方肝胆外科医院肿瘤生物治疗科, 上海 200438

One case of double primary tumors with secondary acute leukemia induced by chemotherapy drugs and literature review

Department of Biotherapy, Eastern Hepatobiliary Surgical Hospital, Shanghai 200438, China

摘要: 近年来,随着化疗的大量开展,继发性白血病发病率逐年升高,笔者报道1例卵巢癌并发乳腺癌患者经化疗、放疗后出现急性粒-单细胞白血病,从初次化疗至诊断急性白血病的时间为37个月,起病急、生存期短。文献报道烷化剂、拓扑异构酶I抑制剂、铂类均易诱发继发性白血病。造血干细胞移植可降低病死率、延长无进展生存期。
- 继发性白血病 /
- 卵巢癌 /
- 乳腺癌 /
- 化疗
Abstract: In recent years, with a large number of chemotherapy development, the incidence of secondary leukemia increased year by year,an acute myelomonocytic leukemia after chemotherapy and radiotherapy in 1 case of ovarian cancer and breast cancer was reported. The time from first chemotherapy to acute leukemia onset was 37 months. This patient had rapid onset and short survival period. Reports in the literature suggested that alkylating agents, topoisomerase I inhibitors, platinum were all easy to induce secondary leukemia. Hematopoietic stem cell transplantation coud reduce mortality and prolong progression free survival.
- secondary leukemia /
- ovarian cancer /
- breast cancer /
- chemotherapy

[1]	Smit CG, Meyler L.Acute myeloid leukaemia after treatment with cytostatic agents[J]. Lancet, 1970, 2(7674):671-672.
[2]	Leone G,Voso MT,Sica S, et al, Therapy related leukemias: susceptibility, prevention and treatment[J]. Leuk Lymphoma, 2001,41 (3-4): 255-276.
[3]	肖志坚,都玉书.继发性白血病的研究现况[J].中华血液学杂志,2001,22(11):613-616.
[4]	Markman M. Chronic myelocytic leukemia as a secondary malignant condition in a patient receiving prolonged chemotherapy for ovarian carcinoma[J]. West J Med,1985,143 (2): 243.
[5]	Atichartakarn V, Punyammalee B, Nitiyanant P. Therapy related acute non-lymphocytic leukemia: report of 4 cases[J].Southeast Asian J Trop Med Public Health,1985, 16(3):421-430.
[6]	夏忠军.卵巢癌化疗的继发性白血病[J].国际内科学杂志,1991,2(3):22-24.
[7]	Chambers SK, Chopyk RL, Chambers JT, et al, Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer[J]. Cancer, 1989,64 (12): 2459-2461.
[8]	Yokoyama Y, Futagami M, Fukushi Y, et al, Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin and cyclophosphamide for stage IV epithelial ovarian cancer[J]. Arch Gynecol Obstet,2000,263 (4): 206-207.
[9]	Travis LB, Holowaty EJ, Bergfeldt K, et al, Risk of leukemia after platinum-based chemotherapy for ovarian cancer[J]. N Engl J Med, 1999,340 (5): 351-357.
[10]	Yeasmin S, Nakayama K, Ishibashi M, et al, Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxel-and carboplatin-based chemotherapy in an ovarian cancer patient: a case report and literature review[J]. Int J Gynecol Cancer, 2008,18 (6): 1371-1376.
[11]	Ishikawa M, Nakayama K, Rahman MT, et al, Therapy-related myelodysplastic syndrome and acute myeloid leukemia following chemotherapy (paclitaxel and carboplatin) and radiation therapy in ovarian cancer: a case report[J]. Eur J Gynaecol Oncol,2014,35 (4): 443-448.
[12]	Vay A, Kumar S, Seward S, et al, Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis[J]. Gynecol Oncol,2011,123 (3): 456-460.

[1]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202401050
[2]	徐飞, 陈瑾, 鲁育含, 李志勇. 肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
[3]	马兹芬, 许维恒, 金煜翔, 薛磊. 食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
[4]	徐璐璐, 刘爱军. 丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2024, 42(12): 1-8. doi: 10.12206/j.issn.2097-2024.202312027
[5]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[6]	陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾. 基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
[7]	冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军. 雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055

点击查看大图

计量

文章访问数: 3495
HTML全文浏览量: 295
PDF下载量: 461
被引次数: 0

化疗药物治疗双原发肿瘤继发急性白血病1例及文献复习

doi: 10.3969/j.issn.1006-0111.2015.05.020

东方肝胆外科医院肿瘤生物治疗科, 上海 200438

收稿日期: 2015-01-12
修回日期: 2015-04-28

关键词:

继发性白血病 /

卵巢癌 /

乳腺癌 /

化疗

摘要: 近年来,随着化疗的大量开展,继发性白血病发病率逐年升高,笔者报道1例卵巢癌并发乳腺癌患者经化疗、放疗后出现急性粒-单细胞白血病,从初次化疗至诊断急性白血病的时间为37个月,起病急、生存期短。文献报道烷化剂、拓扑异构酶I抑制剂、铂类均易诱发继发性白血病。造血干细胞移植可降低病死率、延长无进展生存期。